Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GGT1 | P19440 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28916538 | 1.00 | FFAR3 (0.54) | FFAR3LCKFYNLMNAALOX15 | |
| Acetic Acid SCHEMBL11464476 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNLMNAALOX15 | |
| Tert-Butylamine SCHEMBL27717339 | 0.88 | FFAR3 (0.58) | FFAR3LCKFYNLMNAALOX15 | |
| Acetic Acid SCHEMBL29475783 | 0.88 | FFAR3 (0.58) | FFAR3LCKFYNLMNAALOX15 | |
| Tert-Butylamine SCHEMBL289315 | 0.88 | — | — | |
| Tert-Butylamine SCHEMBL29006209 | 0.85 | FFAR3 (0.54) | FFAR3LCKFYNLMNAALOX15 | |
| Acetic Acid SCHEMBL3731603 | 0.84 | FFAR3 (0.64) | FFAR3LCKFYNLMNAALOX15 | |
| Acetic Acid SCHEMBL442452 | 0.81 | FFAR3 (0.50) | FFAR3LCKFYNLMNAALOX15 | |
| Acetic Acid SCHEMBL7437249 | 0.81 | FFAR3 (0.50) | FFAR3LCKFYNLMNAALOX15 | |
| Acetic Acid SCHEMBL28212914 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1573056-A4 | METHODS FOR FRAGMENTATION, LABELING AND IMMOBILIZATION OF NUCLEIC ACIDS | NUGEN TECHNOLOGIES INC (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070172925-A1 | Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound | NIPPON SHINYAKU CO., LTD. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1710249-A1 | RIBONUCLEIC ACID COMPOUND AND METHOD OF LIQUID-PHASE SYNTHESIS OF OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1573056-A2 | METHODS FOR FRAGMENTATION, LABELING AND IMMOBILIZATION OF NUCLEIC ACIDS | NuGEN Technologies, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004011665-A2 | METHODS FOR FRAGMENTATION, LABELING AND IMMOBILIZATION OF NUCLEIC ACIDS | NUGEN TECHNOLOGIES, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040005614-A1 | Methods for fragmentation, labeling and immobilization of nucleic acids | NUGEN TECHNOLOGIES, INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172925-A1 | Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound | RNASEH1, NSUN2, POLR2H | FFAR3 3614/4885LCK 3619/4885FYN 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.